Neoadjuvant treatment strategies for hepatocellular carcinoma

被引：19
|
作者：
Xu, Lei [1 ]
Chen, Lin [1 ]
Zhang, Wei [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China
来源：
WORLD JOURNAL OF GASTROINTESTINAL SURGERY | 2021年 / 13卷 / 12期
关键词：
Hepatocellular carcinoma; Neoadjuvant therapy; Prognosis; Indications; Contraindications; PORTAL-VEIN EMBOLIZATION; DRUG-ELUTING BEADS; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; GEMCITABINE PLUS OXALIPLATIN; RECURRENCE-FREE SURVIVAL; FATTY LIVER-DISEASE; INFERIOR VENA-CAVA; TRANSARTERIAL CHEMOEMBOLIZATION; Y-90; RADIOEMBOLIZATION; CONVENTIONAL CHEMOEMBOLIZATION;
D O I：
10.4240/wjgs.v13.i12.1550
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The incidence of hepatocellular carcinoma (HCC) remains high globally. Surgical treatment is the best treatment for improving the prognosis of patients with HCC. Neoadjuvant therapy plays a key role in preventing tumor progression and even downstaging HCC. The liver transplantation rate and resectability rate have increased for neoadjuvant therapy. Neoadjuvant therapy is effective in different stages of HCC. In this review, we summarized the definition, methods, effects, indications and contraindications of neoadjuvant therapy in HCC, which have significance for guiding treatment.
引用
收藏
页码：1550 / 1566
页数：17
相关论文
共 50 条
  • [31] Treatment Strategy of Transarterial Chemoembolization for Hepatocellular Carcinoma
    Miyayama, Shiro
    APPLIED SCIENCES-BASEL, 2020, 10 (20): : 1 - 19
  • [32] Therapy options in hepatocellular carcinoma which is not susceptible to curative treatment: current position
    Pesque, S.
    de Baere, T.
    Boige, V.
    ONCOLOGIE, 2010, 12 (10) : 615 - 622
  • [33] Hepatocellular carcinoma-neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome
    Urban, Iveta
    Primavesi, Florian
    Bogner, Klaus
    Bartsch, Claudia
    Trattner, Marlene
    Schmid, Alexandra
    Staettner, Stefan
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (01) : 5 - 11
  • [34] Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma
    Zhao, Hai-Tao
    Cai, Jian-Qiang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (47) : 8069 - 8080
  • [35] Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma
    Chua, Terence C.
    Liauw, Winston
    Saxena, Akshat
    Chu, Francis
    Glenn, Derek
    Chai, Alan
    Morris, David L.
    LIVER INTERNATIONAL, 2010, 30 (02) : 166 - 174
  • [36] Radioembolization for the treatment of hepatocellular carcinoma
    Kim, Hyo-Cheol
    CLINICAL AND MOLECULAR HEPATOLOGY, 2017, 23 (02) : 109 - 114
  • [37] Multimodal treatment of hepatocellular carcinoma
    Graf, Dirk
    Vallboehmer, Daniel
    Knoefel, Wolfram Trudo
    Kroepil, Patric
    Antoch, Gerald
    Sagir, Abdurrahaman
    Haeussinger, Dieter
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (05) : 430 - 437
  • [38] Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis
    Ma, Ya-nan
    Jiang, Xuemei
    Song, Peipei
    Tang, Wei
    BIOSCIENCE TRENDS, 2024, 18 (01) : 21 - 41
  • [39] Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan
    Kudo, Masatoshi
    LIVER CANCER, 2023, 12 (06) : 497 - 509
  • [40] Current surgical treatment strategies for hepatocellular carcinoma in North America
    Adeel S Khan
    Kathryn J Fowler
    William C Chapman
    World Journal of Gastroenterology, 2014, (41) : 15007 - 15017
12345